Drug updated on 12/11/2024
| Dosage Form | Inhalation (oral; 1,000 mL [75 mL DE of hyperpolarized xenon Xe 129 in a volume of 250 mL to 750 mL total xenon]) |
| Drug Class | Hyperpolarized contrast agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- At 3 months post-COVID-19 infection, hyperpolarized xenon Xe 129 magnetic resonance imaging (MRI) detected gas-exchange and ventilation abnormalities in patients.
- At 1 year post-infection, the MRI continued to show persistent gas-exchange and ventilation abnormalities, with ongoing symptoms observed in both hospitalized and non-hospitalized individuals.
- Longitudinal improvements were noted over time, but mean values for gas-exchange, ventilation heterogeneity, and symptoms remained abnormal after 1 year.
- There is no safety information available in the reviewed documents.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Xenoview (xenon Xe 129 hyperpolarized) Prescribing Information. | 2022 | Polarean, Inc., Durham, NC |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Review of Hyperpolarized Pulmonary Functional 129 Xe MR for Long-COVID. | 2024 | Journal of Magnetic Resonance Imaging |